Journal article
SIRPA is a specific cell-surface marker for isolating cardiomyocytes derived from human pluripotent stem cells
NC Dubois, AM Craft, P Sharma, DA Elliott, EG Stanley, AG Elefanty, A Gramolini, G Keller
Nature Biotechnology | NATURE PORTFOLIO | Published : 2011
DOI: 10.1038/nbt.2005
Abstract
To identify cell-surface markers specific to human cardiomyocytes, we screened cardiovascular cell populations derived from human embryonic stem cells (hESCs) against a panel of 370 known CD antibodies. This screen identified the signal-regulatory protein alpha (SIRPA) as a marker expressed specifically on cardiomyocytes derived from hESCs and human induced pluripotent stem cells (hiPSCs), and PECAM, THY1, PDGFRB and ITGA1 as markers of the nonmyocyte population. Cell sorting with an antibody against SIRPA allowed for the enrichment of cardiac precursors and cardiomyocytes from hESC/hiPSC differentiationcultures, yielding populations of up to 98% cardiac troponin T-positive cells. When plate..
View full abstractGrants
Awarded by Canadian Institutes of Health Research
Funding Acknowledgements
We would like to thank members of the Keller laboratory for discussion and critical reading of the manuscript, G. Daley (Harvard Medical School, Boston) for providing the MSC-iPS1 and 38-2 cell line, B. Neel for providing the Sirpa-mutant mice and for discussion and suggestions, L. Ailles, J. Paterson and E. Hyatt from the antibody core facility, R. Hamilton for assistance in obtaining fetal tissue samples and the Sick Kids/UHN Flow Cytometry Facility for their assistance with cell sorting. This work was supported by funding from VistaGen Therapeutics (San Francisco) and by grants from Canadian Institute of Health Research (CIHR, MOP-84524) and Ontario's Ministry of Research and Innovation (MRI, GL2-CBD3P3) to G.K. N.C.D. was supported by a Swiss National Foundation postdoctoral fellowship. A.G. and P.S. were supported by the Heart and Stroke Foundation of Ontario (T6281 and NS6636) and CIHR (MOP-106538). A.G.E., E.G.S. and D.A.E. are supported by grants from the Australian Stem Cell Centre, the National Health and Medical Research Council (NHMRC, Australia) and the National Heart Foundation (Australia). E.G.S. and A.G.E. are Senior Research Fellows of the NHMRC (Australia).